Bharat Biotech on Wednesday announced a partnership with Spain’s Biofabri to develop, manufacture and commercialize a new tuberculosis vaccine in 70 countries. Phase 3 clinical trials are expected to begin in the coming months.
Biofabri is a Zendal Group biopharmaceutical company based in Porriño, Spain, with the aim of researching, developing and manufacturing vaccines for humans. The vaccine would be manufactured and developed by Biofabri in collaboration with the University of Zaragoza, IAVI and the Tuberculosis Vaccine Initiative (TBVI).
The MTBVAC was designed and discovered by the Carlos Martín team from the University of Zaragoza. MTBVAC is one of the most promising in the current global TB vaccine pipeline. The only TB vaccine currently available, the Bacillus Calmette-Guerin (BCG) vaccine, was developed 100 years ago and has limited effectiveness in preventing pulmonary TB in adults, who, along with adolescents, are the biggest spreaders of the disease.
This agreement between Bharat Biotech and Biofabri would guarantee the production and supply of the future vaccine in more than 70 countries worldwide.
dr Krishna Ella, Chairman and CEO of Bharat Biotech, said: “TB infected more than 20% of the world’s population and was the second leading cause of death from infectious diseases after Covid-19.”
Bharat Biotech selected this vaccine candidate because of its advanced stage of clinical development and the very encouraging results from phase 1 and 2 clinical trials, Ella said. Partnering with BioFabri could make MTBVAC a global TB vaccine, Ella said.